selected publications
-
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Blood.
2023
Academic Article
GET IT
Times cited: 5 -
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2022
Academic Article
GET IT
Times cited: 4 -
Unmet mental health needs in patients with advanced B-cell lymphomas.
Palliative & supportive care.
2022
Academic Article
GET IT
Times cited: 2 -
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
Clinical lymphoma, myeloma & leukemia.
2021
Academic Article
GET IT
Times cited: 2 -
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Blood advances.
2021
Academic Article
GET IT
Times cited: 11 -
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
The Lancet. Haematology.
2021
Academic Article
GET IT
Times cited: 8 - Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset. Leukemia & lymphoma. 2021 Academic Article GET IT
- Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
-
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.
Blood advances.
2020
Academic Article
GET IT
Times cited: 13 -
Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma.
Journal of palliative medicine.
2019
Academic Article
GET IT
Times cited: 4 -
Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.
Leukemia & lymphoma.
2019
Letter
GET IT
Times cited: 4 -
Surveillance scanning in lymphoma.
Clinical advances in hematology & oncology : H&O.
2019
Review
GET IT
Times cited: 3 -
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
Leukemia & lymphoma.
2019
Academic Article
GET IT
Times cited: 18 - PET beyond Deauville in diffuse large B-cell lymphoma. Leukemia & lymphoma. 2019 Comment GET IT
-
DLBCL Cell of Origin: What Role Should It Play in Care Today?.
Oncology (Williston Park, N.Y.).
2018
Review
GET IT
Times cited: 16 -
Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 1 -
Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations.
Blood.
2018
Academic Article
GET IT
Times cited: 21 - Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee. British journal of haematology. 2018 Letter GET IT
-
Lymphoma "benchmark" or "bench-smudge"?.
Blood.
2017
Comment
GET IT
Times cited: 7 -
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.
British journal of haematology.
2017
Academic Article
GET IT
Times cited: 10 -
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.
Leukemia & lymphoma.
2017
Letter
GET IT
Times cited: 6 - The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval. Oncology (Williston Park, N.Y.). 2017 Editorial Article GET IT
-
Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.
Cell cycle (Georgetown, Tex.).
2016
Academic Article
GET IT
Times cited: 5 -
Management strategies in patients with diffuse large B-cell lymphoma and severe haemophilia.
Haemophilia : the official journal of the World Federation of Hemophilia.
2015
Letter
GET IT
Times cited: 1 -
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
Leukemia & lymphoma.
2015
Academic Article
GET IT
Times cited: 16 -
Splenic lymphomas: is there still a role for splenectomy?.
Oncology (Williston Park, N.Y.).
2012
Comment
GET IT
Times cited: 2 -
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma.
Leukemia & lymphoma.
2008
Academic Article
GET IT
Times cited: 15 -
Hyperlipemia and oxidation of LDL induce vascular smooth muscle cell growth: an effect mediated by the HLH factor Id3.
Journal of vascular research.
2005
Academic Article
GET IT
Times cited: 24